{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35932253",
  "DateCompleted": {
    "Year": "2022",
    "Month": "08",
    "Day": "09"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "10",
    "Day": "12"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1111/all.15281"
    ],
    "Journal": {
      "ISSN": "1398-9995",
      "JournalIssue": {
        "Volume": "77",
        "Issue": "8",
        "PubDate": {
          "Year": "2022",
          "Month": "Aug"
        }
      },
      "Title": "Allergy",
      "ISOAbbreviation": "Allergy"
    },
    "ArticleTitle": "Correspondence to \"Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus\".",
    "Pagination": {
      "StartPage": "2571",
      "EndPage": "2573",
      "MedlinePgn": "2571-2573"
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-2629-8963"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Griffith University, Southport, Qld, Australia."
          },
          {
            "Identifier": [],
            "Affiliation": "Observational and Pragmatic Research Institute, Singapore City, Singapore."
          }
        ],
        "LastName": "Smith",
        "ForeName": "Peter K",
        "Initials": "PK"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Griffith University, Southport, Qld, Australia."
          }
        ],
        "LastName": "Lesslar",
        "ForeName": "Olivia",
        "Initials": "O"
      },
      {
        "Identifier": [
          "0000-0002-9728-9992"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Griffith University, Southport, Qld, Australia."
          },
          {
            "Identifier": [],
            "Affiliation": "Division of Applied Health Sciences, Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK."
          }
        ],
        "LastName": "Price",
        "ForeName": "David B",
        "Initials": "DB"
      }
    ],
    "PublicationTypeList": [
      "Letter",
      "Comment"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Denmark",
    "MedlineTA": "Allergy",
    "NlmUniqueID": "7804028",
    "ISSNLinking": "0105-4538"
  },
  "CommentsCorrectionsList": [
    {
      "RefSource": "Allergy. 2021 Aug;76(8):2354-2366",
      "PMID": "33730365"
    },
    {
      "RefSource": "Allergy. 2022 Aug;77(8):2574-2575",
      "PMID": "35932252"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "diagnosis"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "diagnosis"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Consensus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "diagnosis"
      ],
      "DescriptorName": "Rhinitis, Allergic"
    },
    {
      "QualifierName": [
        "diagnosis"
      ],
      "DescriptorName": "Rhinitis, Allergic, Perennial"
    }
  ],
  "CoiStatement": "OL declare has no conflicts of interests in relation to this work. PS has no conflicts of interest related to this letter. He has current researcher\u2010initiated funding in mucosal and skin immunology supported by GSK and Sanofi respectively. DBP has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Thermofisher; has consultancy agreements with Airway Vista Secretariat, AstraZeneca, Boehringer Ingelheim, Chiesi, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, GlaxoSmithKline, Mylan, Mundipharma, Novartis, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc, Strategic North Limited, Synapse Research Management Partners S.L., Talos Health Solutions, Theravance and WebMD Global LLC; has grants and unrestricted funding for investigator\u2010initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service; has payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme; has payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis, Thermofisher; has stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals, owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and has 5% shareholding in Timestamp, which develops adherence monitoring technology, is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment, and was an expert witness for GlaxoSmithKline."
}